A5053788832- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Restless Legs Syndrome Research
- Parkinson's Disease Mechanisms and Treatments
- Chronic Lymphocytic Leukemia Research
- Amyotrophic Lateral Sclerosis Research
- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Sleep and Wakefulness Research
- Immune Cell Function and Interaction
- Neurological Disease Mechanisms and Treatments
- Obstructive Sleep Apnea Research
- Sleep and related disorders
- Acute Ischemic Stroke Management
- Chronic Myeloid Leukemia Treatments
- Advanced Neuroimaging Techniques and Applications
Tianjin Medical University
2025
Second Hospital of Tianjin Medical University
2025
Hebei Medical University
2023
Second Hospital of Hebei Medical University
2023
AbbVie (United States)
2023
Pharmacyclics (United States)
2023
7538 Background: Continuous therapy with once-daily ibrutinib (Ibr) is associated long-term PFS in pts B-cell malignancies. Dose reduction a potential AE management approach that may optimize treatment outcomes. We evaluated outcomes dose reductions Ibr-treated cardiac AEs. Methods: Data were pooled for from 10 studies of CLL (n=781), mantle cell lymphoma (MCL; n=250), marginal zone (MZL; n=63) or Waldenström macroglobulinemia (WM; n=169). Cardiac AEs, initial and recurrent, identified by...
This study aimed to explore the characteristics of sleep disorders and their relationship with abnormal white-matter integrity in patients sporadic amyotrophic lateral sclerosis. One hundred thirty-six 80 healthy controls were screened consecutively, 56 43 ultimately analyzed. Sleep confirmed using Pittsburgh quality index, Epworth sleepiness scale, polysomnography; classified into those poor good quality. White-matter was assessed diffusion tensor imaging compared between groups identify...